Predictive Factors of Secukinumab Response in Korean Hidradenitis Suppurativa Patients: Insights from a 48-Week Trial

Predictive Factors of Secukinumab Response in Korean Hidradenitis Suppurativa Patients: Insights from a 48-Week Trial

Authors

  • Ngoc Ha Nguyen Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea 2. Department of Dermatology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam https://orcid.org/0009-0002-4466-9550
  • Sang Gyu Lee Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea https://orcid.org/0000-0002-6237-9031
  • Seoyoon Ham Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea https://orcid.org/0009-0002-5569-9579
  • Ju Hee Lee Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea 2. Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, Republic of Korea https://orcid.org/0000-0002-1739-5956
  • Young In Lee Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea 2. car Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, Republic of Korea https://orcid.org/0000-0001-6831-7379

Keywords:

IHS4-55, Hidradenitis Suppurativa , Secukinumab , HiSCR, NRS30

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels commonly occurring in body folds. The IL-17A inhibitor, secukinumab, has shown efficacy in reducing HS lesions in clinical studies, but data on epidemiologic and patient-specific factors influencing response remain limited.

Objectives: To assess how baseline disease severity, treatment initiation delay, and prior biologics exposure influence clinical response to secukinumab and patterns of antibiotic use.

Materials and Methods: This 48-week real-world prospective trial enrolled 10 Korean patients with moderate-to-severe HS. Patients received secukinumab 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every two weeks. Outcomes included Hidradenitis Suppurativa Clinical Response (HiSCR), a 55% reduction in the International HS Severity Score System (IHS4-55), mean change in abscesses and inflammatory nodules, a ≥ 30% reduction in pain score on a numeric rating scale (NRS30), and duration of concomitant antibiotic use.

Results: At week 48, 90% of patients achieved HiSCR, with 90% meeting the IHS4-55 threshold and 60% reaching the NRS30 criteria. Faster responses were recorded in subjects with Hurley stage II, treatment delays of <10 years, or no prior biologics use, although response rates equalized by week 48. All patients, particularly moderate cases, either discontinued or transitioned to monotherapy with systemic antibiotics.

Conclusions: Secukinumab demonstrated efficacy in alleviating HS symptoms in moderate-to-severe cases. Patients with less severe disease, shorter treatment delays, and/or no prior biological therapy exhibited more rapid initial responses. Additionally, the majority of patients experienced a significant duration of antibiotic cessation, underscoring the importance of early intervention. Future studies with larger populations are required to substantiate these findings.

References

Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. DOI:10.1016/j.jaad.2019.08.090. PMID:31604104

Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19-31. DOI:10.1111/jdv.15233. PMID:30176066

Snyder CL, Chen SX, Porter ML. Obstacles to Early Diagnosis and Treatment of Hidradenitis Suppurativa: Current Perspectives on Improving Clinical Management. Clin Cosmet Investig Dermatol. 2023;16:1833-1841. DOI:10.2147/CCID.S301794. PMID:37483473

Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8-11. DOI:10.1016/j.jaad.2015.07.045. PMID:26470623

Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91-101. DOI:10.1016/j.jaad.2019.02.068. PMID:30872149

Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Rev Clin Immunol. 2016;12(10):1015-26. DOI:10.1080/1744666X.2016.1221762. PMID:27531618

Prens LM, Bouwman K, Aarts P, et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. Br J Dermatol. 2021;185(1):177-184. DOI:10.1111/bjd.19863. PMID:33544917

Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. Biomedicines. 2022;10(2)DOI:10.3390/biomedicines10020455. PMID:35203664

Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. DOI:10.1016/S0140-6736(23)00022-3. PMID:36746171

Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609-611. DOI:10.1111/bjd.17822. PMID:30801662

Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524-1526. DOI:10.1016/j.jaad.2020.02.005. PMID:32044410

Reguiai Z, Fougerousse AC, Maccari F, Becherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750-e751. DOI:10.1111/jdv.16605. PMID:32401354

Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441-e442. DOI:10.1111/jdv.17178. PMID:33594790

Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, et al. Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study. Dermatol Ther (Heidelb). 2023;13(4):1029-1038. DOI:10.1007/s13555-023-00906-2. PMID:36892752

Haselgruber S, Fernandez-Crehuet-Serrano P, Fernandez-Ballesteros MD, et al. Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study. Dermatol Ther (Heidelb). 2024;14(7):1875-1890. DOI:10.1007/s13555-024-01209-w. PMID:38896382

Martora F, Marasca C, Cacciapuoti S, et al. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clin Cosmet Investig Dermatol. 2024;17:159-166. DOI:10.2147/CCID.S449367. PMID:38283798

Calao M, Wilson JL, Spelman L, et al. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PLoS One. 2018;13(7):e0200683. DOI:10.1371/journal.pone.0200683. PMID:30040827

Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989-94. DOI:10.1111/jdv.13216. PMID:26201313

Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401-1409. DOI:10.1111/bjd.15748. PMID:28636793

Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395-401. DOI:10.1111/jdv.18632. PMID:36184889

Shishido-Takahashi N, Garcet S, Cueto I, et al. Hepatocyte Growth Factor Has Unique Functions in Keratinocytes that Differ from those of IL-17A and TNF and May Contribute to Inflammatory Pathways in Hidradenitis Suppurativa. J Invest Dermatol. 2024;DOI:10.1016/j.jid.2024.07.005. PMID:39038532

Marzano A, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study. 2021;184(1):133-140.

Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2018;32(10):1784-1790. DOI:10.1111/jdv.15071. PMID:29761904

Lee JW, Heo YW, Lee JH, Lee S. Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: A nationwide population-based cohort study. J Dermatol. 2023;50(6):778-786. DOI:10.1111/1346-8138.16747. PMID:36806098

Alotaibi HM. Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature. Clin Cosmet Investig Dermatol. 2023;16:545-552. DOI:10.2147/CCID.S402453. PMID:36891064

Berg SH, Balogh EA, Ghamrawi RI, Feldman SR. A review of secukinumab in psoriasis treatment. Immunotherapy. 2021;13(3):201-216. DOI:10.2217/imt-2020-0195. PMID:33203276

Touhouche AT, Chaput B, Rouquet RM, et al. Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. 2020;6(3):164-168.

Marzano AV, Magnoni C, Micali G, et al. Improving hidradenitis suppurativa management: consensus statements from physicians and patients’ perspectives. 2024;316(8):577.

Ocker L, Abu Rached N, Seifert C, Scheel C, Bechara FG. Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review. J Clin Med. 2022;11(23)DOI:10.3390/jcm11237240. PMID:36498816

Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899-941. DOI:10.1111/jdv.20472. PMID:39699926

Erbagci E, Bakay OSK, Hapa FA. Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study. Dermatol Pract Concept. 2025;15(1). DOI:10.5826/dpc.1501a4915. PMID:40117600

Kokolakis G, Martorell A, Kerdel F, et al. 42981 Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 efficacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials. 2023;89(3):AB85.

Published

2025-10-07

Issue

Section

Original Article

How to Cite

1.
Nguyen NH, Lee SG, Ham S, Lee JH, Lee YI. Predictive Factors of Secukinumab Response in Korean Hidradenitis Suppurativa Patients: Insights from a 48-Week Trial. Dermatol Pract Concept. 2025;15:5933. doi:10.5826/dpc.1504a5933

Share